首页|Transient Receptor Potential Vanilloid 1 (TRPV1) as a plausible novel therapeutic target for treating neurological complications in ZikaVirus
Transient Receptor Potential Vanilloid 1 (TRPV1) as a plausible novel therapeutic target for treating neurological complications in ZikaVirus
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NSTL
Zika virus was declared a national emergency by WHO (World Health Organization) in 2016 when its widespread outbreaks and life-threatening complications were reported， especially in newborns and adults。 Numerous studies reported that neuroinflammation is one of the significant root-causes behind its major neurological complications like microcephaly and Guillain-Barre syndrome (GBS)。 In this hypothesis， we propose Transient Receptor Potential Vanilloid 1 channel (TRPV1) as a major culprit in triggering positive inflammatory loop， ultimately leading to sustained neuroinflammation， one of the key clinical findings in Zika induced microce-phalic and GBS patients。 Opening of TRPV1 channel also leads to calcium influx and oxidative stress that ultimately results in cellular apoptosis (like Schwann cell in GBS and developing fetal nerve cells in microcephaly)， ultimately leading to these complications。 Currently， no specific cure exists for these complications。 Most of the antiviral candidates are under clinical trials。 Though there is no direct research on TRPV1 as a cause of Zika virus's neurological complications， but similarity in mechanisms is undeniable。 Thus， exploring pathobiological involvement of TRPV1 channels and various TRPV1 modulators in these complications can possibly prove to be an effective futuristic therapeutic strategy for treatment and management of these life-threatening complications。
NSTL
